Key Highlights 

  • Alumis Inc. reported Q3 2025 results alongside key clinical pipeline developments. 
  • Lead candidate envudeucitinib, a next-generation TYK2 inhibitor, approaches major Phase 3 and Phase 2 clinical data milestones in 2026. 
  • Research and development spending rose as the company accelerated late-stage clinical programs. 
  • Cash, cash equivalents and marketable securities totaled $377.7 million, supporting operations into 2027. 
  • Net loss widened to $110.8 million, reflecting higher clinical development and merger-related expenses. 

Earnings Snapshot: Investment Focused on Clinical Development 

Alumis reported financial results for the third quarter ended September 30, 2025, highlighting continued investment in clinical research as the company advances multiple immunology programs. 

Total revenue reached $2.1 million, primarily from collaboration revenue linked to the company’s licensing agreement with Kaken Pharmaceutical Co., Ltd.. The collaboration reflects a broader industry trend in which early-stage biotech companies leverage partnerships to support drug development. 

Operating expenses expanded as Alumis intensified research efforts. Research and development expenses increased to $97.8 million, up from $87.8 million in the prior-year period, largely due to higher clinical trial costs associated with the Phase 3 ONWARD program and broader pipeline expansion. 

Meanwhile, general and administrative expenses rose to $19.5 million, compared with $10.6 million a year earlier. The increase was driven by personnel expansion, professional services, and stock-based compensation related to the company’s merger with ACELYRIN. 

Reflecting these higher operating costs, Alumis reported a net loss of $110.8 million, compared with a net loss of $93.1 million in the third quarter of 2024. 

Pipeline Progress: TYK2 Platform at the Core 

Alumis’ research strategy centers on targeted therapies for immune-mediated diseases, particularly those based on TYK2 inhibition, an emerging mechanism in immunology drug development. 

The company’s lead candidate, envudeucitinib, is a highly selective oral TYK2 inhibitor designed to treat conditions such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus. 

Clinical results from the Phase 2 STRIDE trial were recently published in the Journal of the American Academy of Dermatology. The studies reported sustained treatment responses and a favourable safety profile in patients with moderate-to-severe psoriasis. 

Such results may strengthen the competitive positioning of envudeucitinib within the rapidly evolving TYK2 inhibitor class, where selective targeting and safety differentiation remain central to long-term therapeutic adoption. 

Beyond envudeucitinib, Alumis continues to develop several pipeline candidates aimed at expanding its presence in immunology and neurology markets. 

Expanding Therapeutic Scope 

The company’s pipeline includes additional programs targeting neuroinflammatory and autoimmune diseases. 

One such candidate, A-005, is designed as a central nervous system-penetrant TYK2 inhibitor. Early-stage data presented at the European Committee for Treatment and Research in Multiple Sclerosis Congress indicated favourable pharmacokinetics and effective TYK2 inhibition while demonstrating the ability to cross the blood-brain barrier. 

These characteristics support Alumis’ plan to initiate a Phase 2 clinical trial in multiple sclerosis during the first half of 2026. 

Another experimental therapy, lonigutamab, targets the insulin-like growth factor-1 receptor (IGF-1R) for the treatment of thyroid eye disease. Early clinical findings were presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting, highlighting initial safety and efficacy signals. 

While these programs remain early in development, they illustrate Alumis’ strategy of expanding its therapeutic footprint across multiple immune-mediated disorders. 

 

Upcoming Clinical Catalysts 

The company expects several important clinical milestones over the next 18 months, which could shape its medium-term development trajectory. 

Most notably, topline Phase 3 data from the ONWARD1 and ONWARD2 trials of envudeucitinib in plaque psoriasis are expected in early 2026. 

These studies represent a key late-stage evaluation of the drug’s efficacy and safety. Positive outcomes could strengthen the program’s regulatory pathway and broaden its commercial potential. 

Additional clinical milestones include: 

  • Phase 2b LUMUS trial results in systemic lupus erythematosus, expected in the third quarter of 2026. 
  • Initiation of a Phase 2 multiple sclerosis trial for A-005 in the first half of 2026. 
  • Potential clinical updates from a third internally developed program anticipated in the second half of 2026. 

Such data events often serve as major valuation catalysts for clinical-stage biotechnology companies, particularly when they involve late-stage trials. 

Liquidity Position and Capital Runway 

Alumis ended the quarter with $377.7 million in cash, cash equivalents and marketable securities, providing a significant liquidity buffer for ongoing clinical development. 

Management indicated that existing capital resources are expected to fund operations into 2027, supporting multiple upcoming clinical readouts across the pipeline. 

Maintaining a multi-year cash runway is particularly important for biotechnology firms, as clinical trials typically require substantial capital investment and long development timelines before potential regulatory approval. 

Structural Risks in the Biotech Model 

Despite promising pipeline progress, Alumis faces structural risks common to clinical-stage biotechnology companies. 

Drug development remains highly uncertain, with regulatory approval dependent on clinical trial outcomes, safety profiles, and long-term efficacy data. Delays or negative trial results could significantly alter the company’s development timeline. 

In addition, sustained research spending is likely to keep operating losses elevated until commercial products reach the market. 

Competition also remains a key consideration. The TYK2 inhibitor class has attracted significant industry attention, with several pharmaceutical companies pursuing similar therapeutic mechanisms. 

As a result, differentiation in safety, dosing convenience, and clinical efficacy will be critical factors shaping future market positioning. 

Outlook 

Alumis is approaching a pivotal period as multiple clinical programs move toward key data readouts. 

If upcoming trials validate the therapeutic potential of its TYK2 inhibitors, the company could strengthen its position within the expanding immunology drug development landscape. 

However, as with many late-stage biotechnology firms, the trajectory of Alumis will likely depend heavily on the outcomes of its clinical pipeline and the pace at which experimental therapies progress toward regulatory approval.